House Republicans have launched an investigation into the Drug Enforcement Administration’s strategy of allowing large quantities of fentanyl to reach the streets as part of efforts to build criminal cases. The inquiry, led by Rep. James Comer of Kentucky, chairman of the House Oversight Committee, focuses on a policing approach that permits the monitoring of major fentanyl shipments without immediate seizure.
On Monday, Comer sent a letter to Attorney General Todd Blanche requesting documents related to this controversial tactic, which whistleblowers within the DEA have criticized. Officials in New Mexico, a state severely affected by the fentanyl epidemic, have raised concerns that agents were ordered to refrain from seizing significant quantities of fentanyl pills, potentially violating Justice Department policies meant to protect public safety.
New Mexico Attorney General Raúl Torrez recently filed a lawsuit against the Justice Department demanding the release of some of the same records sought by the House committee. Comer described the policy of standing down on large shipments as “unconscionable,” arguing that it has contributed to preventable harm and loss of life amid the nation’s deadliest drug crisis.
The investigation follows revelations that between 2023 and 2025, DEA agents in New Mexico monitored critical fentanyl shipments that were allowed to proceed to distribution points as part of longer-term law enforcement operations. This occurred despite the federal government’s public education efforts, including the “One Pill Can Kill” campaign and the White House’s designation of fentanyl as a “weapon of mass destruction” in 2023.
Comer’s records request targets policies implemented during the Biden administration, which he asserts rolled back risk mitigation protocols initially established in 2017 under President Donald Trump. Those earlier guidelines instructed agents to “seize or otherwise prevent the distribution” of fentanyl “as soon as practicable.” In contrast, revisions made in 2024 granted federal law enforcement greater discretion, prioritizing the preservation of investigations over immediate interdiction.
However, reporting indicates that the practice of allowing fentanyl shipments to “walk” persisted into Trump’s second term, notably during an investigation that culminated in what was then the largest fentanyl bust in DEA history, announced in May 2025 by then-Attorney General Pam Bondi. That operation resulted in the seizure of approximately 3 million fentanyl pills, but larger amounts were reportedly allowed to pass through agents’ surveillance.
A former DEA supervisor involved in the Albuquerque case, now a whistleblower, has claimed that the entire drug network could have been dismantled six months earlier had agents acted sooner. In response to the emerging controversy, the Justice Department’s Inspector General has launched a nationwide review to determine if similar investigative tactics have been employed in other regions.
DEA Administrator Terry Cole defended the agency’s approach in an August interview, emphasizing the complexity and legal guidance underpinning such investigations. He stated, “Our investigations are long-term and they are complex and they are done under the guidance of the law. We will continue to do that, but we need to stay 100% focused on the adversary.”
The DEA has not issued a formal response to the recent congressional inquiry or the lawsuit filed by New Mexico authorities.